U.S. markets open in 1 hour 58 minutes

Exagen Inc. (E08A.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
1.8600+0.0600 (+3.33%)
As of 08:16AM CET. Market open.

Exagen Inc.

1261 Liberty Way
Vista, CA 92081
United States
760 560 1501

IndustryDiagnostics & Research
Full Time Employees199

Key Executives

NameTitlePayExercisedYear Born
Dr. Tina S. Nova Ph.D.Executive Chairman of Board59.99kN/A1954
Mr. John AballiCEO, President & Director515.77kN/A1985
Mr. Kamal Adawi M.S., MBACFO & Corporate Secretary446.04kN/A1979
Ryan DouglasInvestors Relations OfficerN/AN/AN/A
Mr. John WegenerSenior Vice President of Sales and MarketingN/AN/A1969
Dr. Andrew L. Concoff FACR, M.D.Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardN/AN/AN/A
Dr. Michael I. Nerenberg M.D.Chief Medical OfficerN/AN/A1955
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Corporate Governance

Exagen Inc.’s ISS Governance QualityScore as of February 1, 2024 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.